Company Overview: Abeona

Industry News

25 May

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical Trial NEW YORK and CLEVELAND, May 25, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare...

Read more

19 May

Abeona Therapeutics to Present at Multiple Upcoming Conferences

NEW YORK and CLEVELAND, May 19, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced that members of the management team will present at the following upcoming conferences: Event: Cell & Gene Exchange Panelist:...

Read more

3 Jan

Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease

NEW YORK, NY and CLEVELAND, OH –(Marketwired – January 03, 2017) – Abeona Therapeutics Inc. (ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona’s...

Read more

15 Nov

Abeona Therapeutics to Present at World Orphan and Drug Congress Europe 2016

NEW YORK, NY and CLEVELAND, OH–(Marketwired – November 15, 2016) – Abeona Therapeutics Inc. (ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, PhD, presenting and VP of Patient Advocacy, Michelle Berg, moderating a panel...

Read more

3 Nov

Abeona Therapeutics to Present at Alliance of Regenerative Medicine 4th Annual Advanced Therapies Investor Day in London, UK

NEW YORK, NY and CLEVELAND, OH–(Marketwired – November 03, 2016) – Abeona Therapeutics Inc. (ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, Ph.D. will be presenting, and joining the Clinical Progress of Gene Therapy...

Read more

2 Nov

Abeona Therapeutics Announces JAMA Publication of Positive Phase 1 Study Results for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

NEW YORK, NY and CLEVELAND, OH–(Marketwired – November 02, 2016) – Abeona Therapeutics Inc. (ABEO): EB-101 Phase 1 clinical trial therapy demonstrated clinical efficacy of 67% healed wounds at 6 month post-treatment, lasting through 12 months, including collagen biomarker expression EB-101 was well tolerated in patients with recessive dystrophic...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address